Vistagen Therapeutics (VTGN) EBITDA Margin (2011 - 2026)

Vistagen Therapeutics has disclosed EBITDA Margin across 10 years of filings, most recently posting 904.34% for Q2 2026.

• In Q2 2026, EBITDA Margin rose 557271.0% year-over-year to 904.34%; the TTM figure through Jun 2026 stood at 2784.33% (up 644879.0% YoY), while the FY2026 annual figure was 5683.69%, up 583339.0% from the prior year.
• EBITDA Margin came in at 904.34% for Q2 2026 at Vistagen Therapeutics, up from 3595.05% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 96633.33% in Q1 2025 to a low of 42802.56% in Q1 2022.
• Average EBITDA Margin over 5 years is 1964.7%, with a median of 6413.59% recorded in 2022.
• Year-over-year, EBITDA Margin surged 10355955 bps in 2025 and plunged 10022839 bps in 2026.
• Over 5 years, EBITDA Margin stood at 5425.83% in 2022, then soared by 65 bps to 1918.25% in 2023, then sank by 237 bps to 6461.54% in 2024, then climbed by 0 bps to 6450.83% in 2025, then jumped by 86 bps to 904.34% in 2026.
• Per Business Quant data, the three most recent EBITDA Margin figures were 904.34% in Q2 2026, 3595.05% in Q1 2026, and 6450.83% in Q4 2025.